Moffitt Cancer Center | Strategic Alliance Partners

May 17, 2023

An expert panel discusses the use of tumor-directed oncolytic therapies for melanoma and cutaneous squamous cell carcinoma.

May 17, 2023

A comprehensive overview of treatment approaches for patients with high-risk melanoma.

May 10, 2023

John Michael "JM" Bryant, MD, expands on the results of the interim analysis of the single-center, single-arm phase 2 trial for patients with grade group 5 prostate cancer treated with the combination of nivolumab and standard of care.

May 10, 2023

Experts on skin cancer discuss valuable end points for determining successful treatments for patients with metastatic melanoma.

May 10, 2023

A panel of skin cancer experts share their thoughts on treatment selection for patients with melanoma.

May 04, 2023

The combination of gedatolisib and fulvestrant with or without palbociclib is under evaluation in the phase 3 VIKTORIA-1 trial for the treatment of patients with PIK3CA-mutated or wild-type hormone receptor–positive/HER2-negative breast cancer who have previously progressed on first-line therapy.

May 03, 2023

Sathya Neelature Sriramareddy, MD, PhD, discusses how the interaction between uveal melanoma cells and the liver microenvironment could influence metastasis growth and therapeutic response.

May 03, 2023

Amanda Bloomer, PhD, discusses the comparison of health-related quality of life outcomes between younger and older adult patients with newly diagnosed colorectal cancer evaluated in the ColoCare study.

May 03, 2023

Closing out their discussion on the management of cutaneous squamous cell carcinoma, expert panelists share clinical pearls and excitement for the future.

May 03, 2023

An expert panel analyzes BRAF/MEK dual inhibitor therapy for the treatment of melanoma.

May 03, 2023

Anna C. Pavlick, DO, discusses factors that impact treatment selection for patients with melanoma.

May 02, 2023

Yayi Zhao, discusses how the prevalence of existing medical conditions and clinical factors may vary by race and effect eligibility for enrollment in clinical trials in patients with cancer.

May 01, 2023

Shahrzad A. Zamani, discusses the prevalence of cancer disparities in patients with cancer in sexual and gender minority populations.

April 26, 2023

Heather Han, MD, discusses prior research with gedatolisib that provided the rationale for the phase 3 VIKTORIA-1 trial (NCT05501886) in patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

April 26, 2023

Niveditha Nerlakanti, discusses the investigation of HDAC inhibitors in osteosarcoma.

April 26, 2023

Marilena Tauro, PhD, discusses the role for ULK3 in regulating autophagy in multiple myeloma.

April 26, 2023

Paul Stewart, PhD, discusses the multiomic landscape of squamous cell lung cancer.

April 26, 2023

Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.

April 26, 2023

Mostafa Nasr, PhD candidate, discusses the development of novel preclinical models of prostate cancer dormancy, and the significance of these outcomes may have on future research in metastatic prostate cancer.

April 26, 2023

Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.